Skip to main content
Premium Trial:

Request an Annual Quote

Allscripts Makes $200M Investment in NantHealth

NEW YORK (GenomeWeb) – Allscripts today announced it has acquired a 10 percent stake in informatics firm NantHealth for $200 million in cash.

NantCapital, an investment firm associated with NantHealth founder Patrick Soon-Shiong, has also invested $100 million in Allscripts. The investments follow an alliance between the firms, announced in March 2015, to integrate NantHealth's Genomic Proteomic Sequencing (GPS Cancer) diagnostic test and Eviti treatment protocol planning tool into Allscripts' electronic medical record and practice management software.

The firms said they will jointly develop application programming interfaces (APIs) between their systems as well as integrate NantTransporter, NantCancer Genome Browser, NantContraster, Paradigm, and GPS Cancer sequencing invitations with the Allscripts platform.

NantCapital's investment has been executed through a private placement of Allscripts common stock, the firm said. Allscripts received gross proceeds of approximately $100 million and said the transaction does not change its 2015 guidance.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.